Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21919686 | 0.81 | EPHX2 (0.36) | EPHX2 | |
| SCHEMBL23350329 | 0.75 | EPHX2 (0.34) | EPHX2 | |
| SCHEMBL21166089 | 0.74 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10200590 | 0.74 | EPHX2 (0.44) | EPHX2PDK1 | |
| SCHEMBL16078152 | 0.70 | EPHX2 (0.42) | EPHX2PDK1 | |
| SCHEMBL10200581 | 0.70 | EPHX2 (0.41) | EPHX2PDK1 | |
| SCHEMBL25763548 | 0.70 | EPHX2 (0.36) | EPHX2 | |
| SCHEMBL12299410 | 0.70 | EPHX2 (0.36) | EPHX2 | |
| SCHEMBL25751548 | 0.70 | EPHX2 (0.36) | EPHX2 | |
| SCHEMBL21165813 | 0.68 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | EPHX2 4064/4885CHRNB2 504/4885CHRNA4 365/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | EPHX2 4064/4885CHRNB2 504/4885CHRNA4 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.